2nd Quarter - Report
VENN STRATEGIES for AVANIR PHARMACEUTICALS, INC.
Firm
Client
Income
$40,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Access to and innovation in biopharmaceuticals, including through policies related to payment, pricing, and clinical trials.
Foreign entity interest: Ownership
| Lobbyist | Covered position, as disclosed |
|---|---|
| GRANT COUCH | — |
| ELIZABETH LEE | — |
| STEPHANIE SILVERMAN | — |
| MICHAEL SPIRA | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| OTSUKA PHARMACEUTICALS CO., LTD | Japan | Japan | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.